Carcinoma, Non-Small-Cell Lung: all 6,645 studies

Page 23 of 67. Open to participants first (1,667), then studies with results posted, then the rest; newest registration first within each.

• A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT02457793Phase 1Results posted
• Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)Active, not recruitingNCT02453282Phase 3Results posted
• Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation TherapyTerminatedNCT02452463Phase 2Results posted
• A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLCCompletedNCT02451930Phase 1Results posted
• LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.CompletedNCT02450903Phase 2Results posted
• A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung CancerCompletedNCT02450539Phase 2Results posted
• Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung CancerCompletedNCT02448303Phase 2Results posted
• Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung CancerCompletedNCT02444741Phase 1/2Results posted
• A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract CancerCompletedNCT02443324Phase 1Results posted
• Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia PacificCompletedNCT02442349Phase 2Results posted
• Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care SettingsCompletedNCT02440854Results posted
• A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung CancerCompletedNCT02439450Phase 1/2Results posted
• S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung CancerCompletedNCT02438722Phase 2/3Results posted
• Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)CompletedNCT02437136Phase 1/2Results posted
• NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung CarcinomaCompletedNCT02434081Phase 2Results posted
• Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3CompletedNCT02426658Phase 2Results posted
• A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung CancerCompletedNCT02424617Phase 1/2Results posted
• A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular CarcinomaCompletedNCT02423343Phase 1/2Results posted
• MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT02422381Phase 1/2Results posted
• Pharmacological Ascorbate for Lung CancerCompletedNCT02420314Phase 2Results posted
• T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI FailureCompletedNCT02418234Results posted
• Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)CompletedNCT02414139Phase 2Results posted
• A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT02412371Phase 1/2Results posted
• A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02411591Phase 1Results posted
• A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)Active, not recruitingNCT02411448Phase 3Results posted
• Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for Head-neck and Lung CancerTerminatedNCT02410382Phase 2Results posted
• An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLCCompletedNCT02409368Phase 2Results posted
• A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)TerminatedNCT02409355Phase 3Results posted
• A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]CompletedNCT02409342Phase 3Results posted
• Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or MesotheliomaTerminatedNCT02408016Phase 1/2Results posted
• AZD2014 and Weekly Paclitaxel in Squamous NSCLCTerminatedNCT02403895Phase 2Results posted
• A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid TumorsCompletedNCT02403271Phase 1/2Results posted
• Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)CompletedNCT02395172Phase 3Results posted
• Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung CancerCompletedNCT02394548Not applicableResults posted
• Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT02393209Phase 1/2Results posted
• A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLCCompletedNCT02392507Phase 2Results posted
• A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLCTerminatedNCT02387216Phase 2Results posted
• Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLCTerminatedNCT02382406Phase 1/2Results posted
• A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]CompletedNCT02367794Phase 3Results posted
• A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02367781Phase 3Results posted
• A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02366143Phase 3Results posted
• A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLCCompletedNCT02364999Phase 3Results posted
• Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to ErlotinibCompletedNCT02364609Phase 1Results posted
• Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung CancerCompletedNCT02358473Phase 1Results posted
• Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo LobectomyCompletedNCT02357992Not applicableResults posted
• Neoadjuvant Itraconazole in Non-small Cell Lung CancerCompletedNCT02357836Early Phase 1Results posted
• Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCsCompletedNCT02350764Phase 2Results posted
• Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)TerminatedNCT02349633Phase 1/2Results posted
• A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLCTerminatedNCT02346370Phase 1Results posted
• Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLCCompletedNCT02343952Phase 2Results posted
• Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLCCompletedNCT02337530Phase 2Results posted
• A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to LeptomeningesCompletedNCT02336451Phase 2Results posted
• Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.TerminatedNCT02335944Phase 1/2Results posted
• Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung CancerTerminatedNCT02323126Phase 2Results posted
• TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet ChemotherapyTerminatedNCT02322281Phase 3Results posted
• A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung CancerCompletedNCT02321540Phase 1/2Results posted
• A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive LabelTerminatedNCT02318368Phase 2Results posted
• Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung CancerCompletedNCT02317016Phase 1Results posted
• A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLCCompletedNCT02314364Phase 2Results posted
• Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast CancerCompletedNCT02312622Phase 2Results posted
• A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLCTerminatedNCT02309892Phase 1Results posted
• A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the BrainCompletedNCT02308020Phase 2Results posted
• Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North AfricaCompletedNCT02304406Results posted
• Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line ChemotherapyCompletedNCT02300298Phase 1Results posted
• Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung CancerCompletedNCT02299141Phase 2Results posted
• A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02289833Phase 2Results posted
• Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2CompletedNCT02289456Phase 2Results posted
• Metformin in Non Small Cell Lung Cancer (NSCLC)TerminatedNCT02285855Phase 2Results posted
• GIOTRIF rPMS in Korean Patients With NSCLCCompletedNCT02285361Results posted
• BrUOG L301 With Non-Small Cell Lung Cancer and Bone MetastasesCompletedNCT02283749Phase 2Results posted
• Cisplatin and Nab-paclitaxel for (N2) Defined NSCLCTerminatedNCT02276560Phase 2Results posted
• Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung CancerTerminatedNCT02274038Not applicableResults posted
• Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLCCompletedNCT02273375Phase 3Results posted
• Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung CancerCompletedNCT02272413Phase 3Results posted
• Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former SmokersCompletedNCT02264990Phase 3Results posted
• Icotinib for Completed Resected IB NSCLC With EGFR MutationCompletedNCT02264210Phase 2Results posted
• Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for SurgeryCompletedNCT02262325Phase 2Results posted
• Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung CancerTerminatedNCT02262000Not applicableResults posted
• Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLCActive, not recruitingNCT02259621Phase 2Results posted
• Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung CancerCompletedNCT02250326Phase 2Results posted
• LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational ResearchTerminatedNCT02231164Phase 3Results posted
• Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedNCT02221739Phase 1/2Results posted
• Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)CompletedNCT02220894Phase 3Results posted
• Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationCompletedNCT02208843Phase 4Results posted
• Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLCCompletedNCT02197247Phase 1Results posted
• Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLCCompletedNCT02197234Phase 1Results posted
• Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in KoreaCompletedNCT02196675Results posted
• Cancer Associated Thrombosis and Isoquercetin (CATIQ)CompletedNCT02195232Phase 2/3Results posted
• Pazopanib in Molecularly Selected Patients With Advanced NSCLCTerminatedNCT02193152Phase 2Results posted
• Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and SarcomasTerminatedNCT02192541Phase 1Results posted
• Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)CompletedNCT02191891Phase 1Results posted
• Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung CancerCompletedNCT02186847Phase 2Results posted
• TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed TherapyTerminatedNCT02186301Phase 2/3Results posted
• A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the LungCompletedNCT02185690Phase 1Results posted
• Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung CancerCompletedNCT02179671Phase 2Results posted
• ONO-4538 Study in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT02175017Phase 2Results posted
• Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung CancerCompletedNCT02163733Phase 1Results posted
• Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)CompletedNCT02157883Phase 1Results posted
• Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung CancerTerminatedNCT02157116Phase 2Results posted
• A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung CancerActive, not recruitingNCT02152631Phase 3Results posted

← Carcinoma, Non-Small-Cell Lung overview